Lonza Group AG
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
LONN | SW
Overview
Corporate Details
- ISIN(s):
- CH0013841017 (+2 more)
- LEI:
- 549300EFW4H2TCZ71055
- Country:
- Switzerland
- Address:
- MÜNCHENSTEINERSTR. 38, 4052 BASEL
- Website:
- https://www.lonza.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Lonza Group AG is a Swiss multinational company and a leading global Contract Development and Manufacturing Organization (CDMO) serving the pharmaceutical, biotechnology, and nutrition industries. The company provides integrated services that span from early-stage development to the commercial manufacturing of drug substances and drug products. Lonza specializes in a wide range of advanced technologies, including mammalian and microbial biologics, small molecules, highly potent active pharmaceutical ingredients (APIs), bioconjugates, mRNA, and cell and gene therapies. Founded in 1897, Lonza leverages its extensive scientific and manufacturing expertise to enable its customers to bring innovative and life-enhancing therapies to market for patients worldwide.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Lonza Group AG and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
2025-09-12 09:00 |
Board/Management Information
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez …
|
English | 22.8 KB | |
2025-09-12 02:00 |
Board/Management Information
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez …
|
English | 18.8 KB | |
2025-07-23 06:30 |
Earnings Release
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sale…
|
English | 42.2 KB | |
2025-07-23 02:00 |
Earnings Release
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sale…
|
English | 37.0 KB | |
2025-07-23 02:00 |
Earnings Release
Lonza erzielt starkes Ergebnis im ersten Halbjahr 2025 und erhöht Umsatz- und M…
|
German | 36.9 KB | |
2025-05-27 07:00 |
Earnings Release
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Stru…
|
English | 12.7 KB | |
2025-05-27 02:00 |
Regulatory News Service
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Stru…
|
English | 9.7 KB | |
2025-05-15 09:00 |
Board/Management Information
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
|
English | 14.6 KB | |
2025-05-15 02:00 |
Board/Management Information
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
|
English | 11.0 KB | |
2025-05-10 16:30 |
Post-Annual General Meeting Information
Lonza Announces Results of the 2025 Annual General Meeting All Motions Propose…
|
English | 16.3 KB | |
2025-05-09 06:30 |
Earnings Release
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in L…
|
English | 15.2 KB | |
2025-05-09 02:00 |
Earnings Release
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in L…
|
English | 12.5 KB | |
2025-04-03 07:00 |
Report Publication Announcement
Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual a…
|
English | 20.1 KB | |
2025-04-02 14:00 |
Regulatory News Service
Lonza Implements its Simplified and Streamlined Operating Model
|
English | 16.3 KB | |
2025-04-01 07:00 |
Transaction in Own Shares
Lonza Completes its Share Buyback Program
|
English | 12.2 KB |
Automate Your Workflow. Get a real-time feed of all Lonza Group AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Lonza Group AG via our API.
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
2025-03-14 | N/A | Executive member | Buy | None | 147,442.00 CHF |
2025-03-13 | N/A | Executive member | Buy | None | 107,906.00 CHF |
2025-03-12 | N/A | Executive member | Buy | None | 146,239.00 CHF |
2025-03-11 | N/A | Executive member | Buy | None | 382,476.00 CHF |
2025-03-10 | N/A | Executive member | Buy | None | 771,722.40 CHF |
2025-03-07 | N/A | Executive member | Buy | None | 338,476.00 CHF |
2025-03-06 | N/A | Executive member | Buy | None | 313,416.00 CHF |
2025-02-18 | N/A | Executive member | Buy | None | 164,554.00 CHF |
2025-02-14 | N/A | Executive member | Buy | None | 130,606.00 CHF |
2025-02-13 | N/A | Executive member | Buy | None | 29,500.00 CHF |